Skip to main content

Dyne Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Jul 28, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Jul 28, 2025

DYN$18.62+3.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except share and per share data)

June 30,December 31,
20252024
Assets
Current assets:
Cash and cash equivalents$485,040$435,449
Marketable securities198,885206,819
Prepaid expenses and other current assets14,02517,011
Total current assets697,950659,279
Property and equipment, net5,6755,398
Right-of-use assets22,85924,615
Restricted cash and other assets2,5081,942
Total assets$728,992$691,234
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable14,0166,562
Accrued expenses and other current liabilities22,45430,846
Lease liabilities5,0024,850
Total current liabilities41,47242,258
Long-term debt, net98,813—
Lease liabilities, net of current portion17,26219,138
Total liabilities157,54761,396
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2025 and December 31, 2024——
Common stock, $0.0001 par value; 200,000,000 shares authorized at June 30, 2025 and December 31, 2024; 114,338,610 and 102,318,629 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively1110
Additional paid-in capital1,747,3281,579,750
Accumulated other comprehensive loss2526
Accumulated deficit(1,176,146)(949,928)
Total stockholders’ equity571,445629,838
Total liabilities and stockholders’ equity$728,992$691,234
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.